Want to see TYRA full AI Analyst Report?
TYRA Stock Chart & Stats
$35.56
-$0.12(-0.75%)
At close: 4:00 PM EST
$35.56
-$0.12(-0.75%)
Day’s Range― - ―
52-Week Range$9.96 - $40.65
Previous CloseN/A
Volume80.11K
Average Volume (3M)370.94K
Market Cap
$1.91B
Enterprise Value$1.99K
Total Cash (Recent Filing)$383.47M
Total Debt (Recent Filing)$5.70M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 06, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding59,470,383
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$49.88Price Target Upside40.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and sizable assets/equity provide a durable financial cushion to support multi-year clinical programs. With limited interest burden, the balance sheet reduces near-term solvency risk and gives management time to advance trials or pursue partnerships before needing emergency financing.
Proprietary SNÅP Platform & FGFR PipelineA proprietary discovery engine focused on FGFR biology and assets addressing acquired resistance create structural differentiation. Platform-driven candidate generation plus multiple FGFR programs increases optionality for licensing, partnerships, and staged clinical value creation across indications.
Experienced Board Addition & Governance ContinuityAdding a seasoned biopharma executive and maintaining board/audit continuity strengthens long-term governance and strategic oversight. Improved board expertise supports clinical development decisions, partner engagement, and credible oversight of capital allocation across programs.
Bears Say
Pre-revenue With Expanding LossesZero product revenue and widening operating losses mean the business model is not yet self-sustaining. Persistent negative returns on equity and escalating operating deficits increase reliance on external capital and raise the stakes for clinical success to deliver long-term value.
Substantial Cash Burn & Negative Free Cash FlowHigh and rising cash outflows to fund R&D create ongoing financing needs. Sustained negative cash generation necessitates frequent capital raises, can force prioritization or delays in trials, and amplifies execution risk if capital markets or partner options tighten over the coming months.
Dependence On Equity Financing / Dilution RiskReliance on equity financings is structural for a pre-commercial biotech; while recent proceeds extend runway, repeated raises dilute existing holders and constrain long-term upside. This financing pattern can influence strategic choices and investor returns if clinical timelines slip.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $9.96 and its highest was $40.65 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $1.91B.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Tyra Bioscience’s earnings last quarter?
Tyra Bioscience released its earnings results on May 13, 2026. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.588 by -$0.052.
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate is -0.65.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 59,470,383 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Tyra Bioscience reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.588. Following the earnings report the stock price went up 3.785%.
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tyra Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.88 (40.26% Upside)
$49.88 (40.26% Upside)
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.61%
12-Months-Change
Fundamentals
Return on Equity
-42.66%
Trailing 12-Months
Asset Growth
19.96%
Trailing 12-Months
Company Description
Tyra Bioscience
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$49.88
▲(40.26% Upside)
Technical Analysis
Ownership Overview
29.85% Insiders
16.39% Mutual Funds
0.08% Other Institutional Investors
43.50% Public Companies and
Individual Investors